4. ONGOING RESEARCH
Literature Review in R&D
Limitation of Previous Research
Short Term(2001~2006), Short Time Interval, Stock Value 450%↑
New drug(at Least *11.8 years)
* A. DiMasi, R. W. Hansen and H. G. Grabowski, "The price of innovation: new estimates of drug development
costs," Journal of Health Economics, 22(2), 2003, pp. 151-85
5. ONGOING RESEARCH
(1) Determinating equation of R&D (2) Determinating equation of Corporate
Investment performance
Variable Description Variable Description
Y1 R&D investment Y2 Ordinary income
X1 T year- Government R&D support Z1 t year R&D investment
X2 T year- Government R&D support Z2 T-1 year R&D investment
X3 # of Researcher Z3 (Dummy)New drug
X4 The ratio of owner's equity Z4 (Dummy)GMP
X5(=Y2) Ordinary income
6. RESEARCH PLAN
Current Research Topics
Open Innovation for R&D in the Pharm. Industry
Global Innovation Network: China, India
Strategic Model
Categorization of R&D Architecture Model
Worldwide Comparative Studies in the Pharm. Industry
Biosimilar & Bio New Drug
Quantitative Marketing, Pricing and R&D Simulation
7. RESEARCH PLAN
Future Study Plan:
Advisor: Prof. Minki Kim
Plan for Research Methodology
Main Textbooks
Microeconometrics : Methods and Applications By A. Colin Cameron, and Pravin K.
Trivedi
Microeconometrics Using Stata By A. Colin Cameron, and Pravin K. Trivedi
Discrete Choice Methods with Simulation Trivedi By Train, K. E
Coursework
2012 Spring 2012 Fall
ITM702: Advanced Econometrics
Research MAS550: Probability Theory (Mathematical Science
IE532:Modeling & Simulation(Industrial &
s)
Methodology Systems Eng.)
ITM601: Research MethodologiesⅠ
ITM701: Research MethodologiesⅡ
ITM631: Case Studies of Open Innovation
이주성 교수님
Industry ITM525: Bio-Medical Technology Foresigh
ITM660: Strategic Management of High-Tech I
Study t
nnovation
김원준 교수님